Answers are grounded in this paper and cite their sources.
Introduction Health Technology Assessment (HTA) and pharmacovigilance are traditionally considered distinct domains within the lifecycle of medicinal products, focusing, respectively, on value assessment for reimbursement and post-marketing safety surveillance. However, the increasing availability of real-world data (RWD) and real-world evidence (RWE) is progressively blurring the boundaries between these disciplines, enabling a more integrated and dynamic evaluation of health technologies. Objective This overview explores the conceptual and methodological intersections between HTA and pharmacovigilance, with particular emphasis on the role of RWE generated from routine clinical practice. Methods, Overview, Results Evidence derived from pharmacovigilance activities, including spontaneous reporting systems, post-authorization safety studies, patient registries, and large healthcare databases, provides critical insights into long-term safety, effectiveness, and treatment utilization patterns that are often not fully captured in pre-marketing clinical trials. These data can meaningfully inform HTA processes by refining benefit–risk assessments, addressing evidence gaps at the time of reimbursement decisions, and supporting lifecycle reassessment of technologies. Furthermore, emerging analytical approaches, including artificial intelligence and advanced pharmacoepidemiological methods, offer new opportunities to enhance the quality, timeliness, and interpretability of RWE for both regulatory and HTA purposes. Despite these advances, significant challenges remain, including data quality, methodological heterogeneity, governance frameworks, and alignment between regulatory and HTA requirements. Conclusions Strengthening the integration of pharmacovigilance-derived evidence into HTA frameworks may support more adaptive, transparent, and value-based decision-making, ultimately improving patient safety and the sustainability of healthcare systems.
No takes yet. Share an insight, caveat, or question.
Castellana et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: